Sign In
Buy SRPT
$16.24
-0.0100 (-0.0615%)
At Close: Jun 03, 2026
Sarepta Therapeutics to Participate in Upcoming Investor Conferences
04:30pm, Monday, 01'st Jun 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in the
My Top 3 Biotech Stocks for May 2026
11:15am, Wednesday, 20'th May 2026
As FDA activity accelerates and big pharma searches for its next generation of blockbuster drugs, select biotech companies are beginning to stand out from the crowd.
Sarepta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference
04:30pm, Wednesday, 13'th May 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fi
Sarepta's Q1 Earnings & Sales Beat Estimates, '26 Outlook Maintained
11:51am, Thursday, 07'th May 2026
SRPT beats Q1 earnings and revenue estimates despite a sharp Elevidys sales drop, while maintaining its 2026 product revenue outlook.
Sarepta Therapeutics, Inc. (SRPT) Q1 2026 Earnings Call Transcript
11:41pm, Wednesday, 06'th May 2026
Sarepta Therapeutics, Inc. (SRPT) Q1 2026 Earnings Call Transcript
Sarepta Therapeutics (SRPT) Reports Q1 Earnings: What Key Metrics Have to Say
07:31pm, Wednesday, 06'th May 2026
The headline numbers for Sarepta Therapeutics (SRPT) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall St
Sarepta Therapeutics (SRPT) Q1 Earnings and Revenues Top Estimates
06:25pm, Wednesday, 06'th May 2026
Sarepta Therapeutics (SRPT) came out with quarterly earnings of $3.16 per share, beating the Zacks Consensus Estimate of $0.9 per share. This compares to a loss of $3.42 per share a year ago.
Sarepta Therapeutics Announces First Quarter 2026 Financial Results and Recent Corporate Developments
04:05pm, Wednesday, 06'th May 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the first quarter 2026. "W
Sarepta Therapeutics (SRPT) Reports Next Week: Wall Street Expects Earnings Growth
11:02am, Wednesday, 29'th Apr 2026
Sarepta Therapeutics (SRPT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Sarepta Therapeutics to Announce First Quarter 2026 Financial Results
08:30am, Wednesday, 22'nd Apr 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report first quarter 2026 financial results after the Nasd
Aberdeen Group plc Increases Stake in Sarepta Therapeutics, Inc. $SRPT
03:54am, Saturday, 04'th Apr 2026
Aberdeen Group plc increased its position in shares of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) by 13.6% in the fourth quarter, according to the company in its most recent filing with the Securities
5 Biotechs That Big Pharma Could Snap Up as Oncology M&A Heats Up
07:05am, Wednesday, 01'st Apr 2026
Oncology M&A activity is accelerating as large pharmaceutical companies race to replenish pipelines facing patent cliffs and seek exposure to next-generation therapeutic platforms.
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Tuesday, 31'st Mar 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on March 31, 2026 that were previously ap
MRNA, SRPT, and KRYS Phase 3 Data Will Shape XBI's 2026 Performance
08:15am, Sunday, 29'th Mar 2026
SPDR S&P Biotech ETF (NYSEARCA:XBI) is built around a deceptively simple idea: give every biotech company roughly equal footing, regardless of size.
Why Is Sarepta Therapeutics (SRPT) Up 24.2% Since Last Earnings Report?
12:31pm, Friday, 27'th Mar 2026
Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock?
